AbstractPatients with advanced Hodgkin's disease not achieving a complete remission with initial MOPP therapy are significantly less responsive to adriamycin and nitrosourea-containing regimens than patients with relapsing disease following a complete remission with MOPP. Hodgkin's disease not responding completely to initial four-drug treatment represents resistant disease which, in most instances, may not be cured with existing alternative chemotherapy. These patients should receive innovative treatment.